Skip to main content

Warning notification:Warning

Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:

  1. Chrome
  2. Edge
  3. FireFox
  4. Opera
  5. Safari

Neuroendocrine SACT Regimens

Everolimus Monotherapy

Regimen

Indication

00320b

Treatment of unresectable or metastatic, well or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.

00320c

The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease.

Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy

Regimen

Indication

00642a

Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive-gastroenteropancreatic neuroendocrine tumours (GEP- NETs) in adults.

SUNitinib 37.5mg Therapy - 28 days

Regimen

Indication

00327a

Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults

Back to National Cancer Control Programme